Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Argent Biopharma ( (AU:RGT) ) has issued an update.
Argent BioPharma has reported that all resolutions presented at its 8 April 2026 general meeting of shareholders were passed by poll, reflecting broad investor support for the company’s strategic initiatives. The approved motions include multiple share issuances tied to the CannPal acquisition, the NeuVis option, allocations to key executives and partners, and the ratification of prior security issues, collectively reinforcing Argent’s capital structure and providing flexibility to advance its clinical pipeline and growth plans.
The most recent analyst rating on (AU:RGT) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
More about Argent Biopharma
Argent BioPharma Ltd. is a clinical-stage biopharmaceutical company developing nano-engineered medicines aimed at restoring balance between the nervous and immune systems. Its lead candidates, CannEpil for drug-resistant epilepsy and CimetrA for cytokine-driven inflammatory and autoimmune disorders, leverage proprietary delivery platforms designed to enhance penetration across critical biological barriers and address urgent unmet needs in CNS and systemic inflammation.
Average Trading Volume: 189,091
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$3.39M
For a thorough assessment of RGT stock, go to TipRanks’ Stock Analysis page.